Non-Genomic Actions of the Androgen Receptor in Prostate Cancer
Jacky K Leung1, Marianne D Sadar1
1Department of Genome Sciences Centre, British Columbia Cancer Agency , Vancouver, BC , Canada.
Abstract:
Androgen receptor (AR) is a validated drug target for prostate cancer based on its role in proliferation, survival, and metastases of prostate cancer cells. Unfortunately, despite recent improvements to androgen deprivation therapy and the advent of better antiandrogens with a superior affinity for the AR ligand-binding domain (LBD), most patients with recurrent disease will eventually develop lethal metastatic castration-resistant prostate cancer (CRPC). Expression of constitutively active AR splice variants that lack the LBD contribute toward therapeutic resistance by bypassing androgen blockade and antiandrogens. In the canonical pathway, binding of androgen to AR LBD triggers the release of AR from molecular chaperones which enable conformational changes and protein-protein interactions to facilitate its nuclear translocation where it regulates the expression of target genes. However, preceding AR function in the nucleus, initial binding of androgen to AR LBD in the cytoplasm may already initiate signal transduction pathways to modulate cellular proliferation and migration. In this article, we review the significance of signal transduction pathways activated by rapid, non-genomic signaling of the AR during the progression to metastatic CRPC and put into perspective the implications for current and novel therapies that target different domains of AR.
Insights
Androgen receptor (AR) signaling drives prostate cancer progression. Understanding rapid, non-genomic AR pathways is crucial for developing new therapies against castration-resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Androgen receptor (AR) is a key target in prostate cancer, crucial for cancer cell proliferation, survival, and metastasis.
- Despite advancements in androgen deprivation therapy and antiandrogens, most patients develop lethal castration-resistant prostate cancer (CRPC).
- AR splice variants lacking the ligand-binding domain (LBD) confer therapeutic resistance by bypassing current treatments.
Purpose of the Study:
- To review the significance of signal transduction pathways activated by rapid, non-genomic AR signaling.
- To discuss the implications for current and novel therapies targeting different AR domains during CRPC progression.
Main Methods:
- Review of existing literature on AR signaling pathways.
- Analysis of the role of non-genomic AR signaling in prostate cancer progression.
- Evaluation of therapeutic strategies targeting AR.
Main Results:
- Non-genomic AR signaling, initiated by androgen binding to the AR LBD in the cytoplasm, can modulate cellular proliferation and migration.
- These rapid signaling pathways precede AR's nuclear function and gene regulation.
- Understanding these pathways is vital for overcoming therapeutic resistance in CRPC.
Conclusions:
- Rapid, non-genomic AR signaling plays a significant role in the progression to metastatic CRPC.
- Targeting different domains of the AR, beyond the LBD, may offer novel therapeutic strategies.
- Further research into non-genomic AR pathways is warranted for improved CRPC treatment.
Related Concept Videos
01:31Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
01:08Intracellular Hormone Receptors
01:31Internal Receptors